keyword
MENU ▼
Read by QxMD icon Read
search

Nilotinib

keyword
https://www.readbyqxmd.com/read/29222244/cardiovascular-care-of-patients-with-chronic-myeloid-leukemia-cml-on-tyrosine-kinase-inhibitor-tki-therapy
#1
REVIEW
Mary C Barber, Michael J Mauro, Javid Moslehi
Cardiovascular (CV) health has emerged as an important consideration in patients with chronic myeloid leukemia (CML) because of improved prognosis. Indeed, the success of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has increased the focus on survivorship and late toxicity in oncological care. Survivorship issues in this population include CV disease prevention, given its prevalence in the general population. The introduction of BCR-ABL1 TKIs represented a unique concept of indefinite cancer therapy, only recently evolving to include "treatment-free remission...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29220734/high-throughput-routine-determination-of-17-tyrosine-kinase-inhibitors-by-lc-ms-ms
#2
Camille Merienne, Marine Rousset, Dominique Ducint, Nadège Castaing, Karine Titier, Mathieu Molimard, Stéphane Bouchet
Several studies have shown that therapeutic drug monitoring of tyrosine kinase inhibitors (TKI) can improve their benefit in cancer. An analytical tool has been developed in order to quantify 17 tyrosine kinase inhibitors and 2 metabolites in human plasma (afatinib, axitinib, bosutinib, crizotinib, dabrafenib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, ponatinib, regorafenib, regorafenib M2, regorafenib M5, ruxolitinib, sorafenib, sunitinib, vandetanib). Drugs were arranged in four groups, according to their plasma concentration range: 0...
November 28, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29212733/successful-ovarian-stimulation-for-fertility-preservation-in-a-patient-with-chronic-myeloid-leukemia-switch-from-nilotinib-to-interferon-%C3%AE
#3
Smaranda Gazdaru, Lucien Perey, Anne Rosselet, Patrice Mathevet, Yves Chalandon, Nicolas Vulliemoz
The development of tyrosine-kinase inhibitors (TKIs) has improved survival of patients with chronic myeloid leukemia (CML). Some patients may become resistant to TKIs and require hematopoietic stem cell transplant (HSCT) that is highly gonadotoxic. Fertility preservation with ovarian stimulation might be indicated but is challenging if patients need to remain on TKIs until HSCT because TKIs may compromise follicular development and response to ovarian stimulation. We report the case of a patient with CML resistant to TKI and planned for an HSCT, in which treatment by TKI was replaced by interferon-α before and during ovarian stimulation for fertility preservation...
December 6, 2017: Oncologist
https://www.readbyqxmd.com/read/29200684/the-role-of-mutation-testing-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-after-imatinib-failure-and-their-outcomes-after-treatment-modification-single-institutional-experience-over-13-years
#4
Puligundla Krishna Chaitanya, Karnam Ashok Kumar, Bala Stalin, Gundeti Sadashivudu, Maddali Lakshmi Srinivas
Introduction: BCR-ABL1 kinase domain mutations represent the most frequent mechanism of resistance to tyrosine kinase inhibitor (TKI) therapy, being detected in 40%-50% of imatinib-resistant patients with chronic myeloid leukemia in chronic phase (CML-CP). Over 100 BCR-ABL1 single-point mutations have been reported in patients with imatinib-resistant CML. There were few studies reported from India on BCR-ABL kinase mutations in imatinib failure patients. We present our data on imatinib resistance mutation analysis (IRMA) and use of imatinib dose hike and 2nd-generation TKI at our institute...
July 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/29199677/effect-of-tyrosine-kinase-inhibitors-on-the-glucose-levels-in-diabetic-and-nondiabetic-patients
#5
E Y Romero-Ventosa, L Otero-Millán, S González-Costas, P Vilasoa-Boo, A Silva-López, C Arroyo-Conde, G Piñeiro-Corrales
CONTEXT: Tyrosine kinase inhibitors (TKIs) are used in different types of cancers due to their good profile of adverse reactions and their convenience in the oral administration. Some studies describe that certain TKIs are associated with changes in the glycemic profile of the patients. AIMS: This study aims to determine if treatment with ITK affects to serum glucose levels in clinical practice. SETTINGS AND DESIGN: A retrospective study was carried out in 136 episodes (112 patients treated with sorafenib, sunitinib, imatinib, dasatinib, or nilotinib)...
January 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/29192124/drugs-and-scaffold-that-inhibit-cytochrome-p450-27a1-cyp27a1-in-vitro-and-in-vivo
#6
Morrie Lam, Natalia Mast, Irina Pikuleva
Cytochrome P450 27A1 (CYP27A1) is a ubiquitous enzyme that hydroxylates cholesterol and other sterols. Complete CYP27A1 deficiency due to genetic mutations is detrimental to human health, whereas 50% of activity retention is not and does not affect the whole body cholesterol levels. CYP27A1 is considered as a potential therapeutic target in breast cancer and age-related neurodegenerative diseases; however CYP27A1 inhibition should be 50%. Herein, 131 pharmaceuticals were tested for their effect on CYP27A1-mediated cholesterol 27-hydroxylation by in vitro enzyme assay...
November 30, 2017: Molecular Pharmacology
https://www.readbyqxmd.com/read/29185155/successful-treatment-of-follicular-lymphoma-with-second-generation-tyrosine-kinase-inhibitors-administered-for-coexisting-chronic-myeloid-leukemia
#7
Shin-Ichiro Fujiwara, Yuya Shirato, Takashi Ikeda, Shin-Ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Shin-Ichi Ochi, Takashi Nagayama, Kiyomi Mashima, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Ken Ohmine, Kazuo Muroi, Yoshinobu Kanda
Tyrosine kinase inhibitors (TKIs) are standard therapy for chronic myeloid leukemia (CML). However, the effects of these agents on mature B cell lymphoma are not well known. We describe a 50-year-old man who was diagnosed with CML in the chronic phase and treated with imatinib. After 3 years of imatinib therapy that achieved a complete cytogenetic response of CML, he developed Philadelphia-negative follicular lymphoma (FL). Rituximab monotherapy induced a partial response of FL, and he subsequently achieved a major molecular response (MMR) of CML...
November 28, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29168352/patient-satisfaction-with-information-on-oral-anticancer-agent-use
#8
Christel C L M Boons, Lonneke Timmers, Natasja M van Schoor, Eleonora L Swart, N Harry Hendrikse, Jeroen J W M Janssen, Jacqueline G Hugtenburg
Adequate information on oral anticancer agent (OACA) use is an essential element of optimal cancer care. The present study aimed to get insight into the experiences of patients with information on OACA treatment and their characteristics regarding information dissatisfaction. Patients of four Dutch university hospitals using OACA participated in this observational study and completed the Satisfaction with Information about Medicines Scale (SIMS), EORTC Quality of Life Questionnaire-C30, Brief Illness Perception Questionnaire, and Beliefs about Medicines Questionnaire-Specific...
November 23, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/29165716/targeting-bcr-abl-independent-tki-resistance-in-chronic-myeloid-leukemia-by-mtor-and-autophagy-inhibition
#9
Rebecca Mitchell, Lisa E M Hopcroft, Pablo Baquero, Elaine K Allan, Kay Hewit, Daniel James, Graham Hamilton, Arunima Mukhopadhyay, Jim O'Prey, Alan Hair, Junia V Melo, Edmond Chan, Kevin M Ryan, Véronique Maguer-Satta, Brian J Druker, Richard E Clark, Subir Mitra, Pawel Herzyk, Franck E Nicolini, Paolo Salomoni, G Vignir Helgason
Background: Imatinib and second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib have statistically significantly improved the life expectancy of chronic myeloid leukemia (CML) patients; however, resistance to TKIs remains a major clinical challenge. Although ponatinib, a third-generation TKI, improves outcomes for patients with BCR-ABL-dependent mechanisms of resistance, including the T315I mutation, a proportion of patients may have or develop BCR-ABL-independent resistance and fail ponatinib treatment...
November 20, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29152138/the-hoct1-and-abcb1-polymorphisms-do-not-influence-the-pharmacodynamics-of-nilotinib-in-chronic-myeloid-leukemia
#10
Sara Galimberti, Cristina Bucelli, Elena Arrigoni, Claudia Baratè, Susanna Grassi, Federica Ricci, Francesca Guerrini, Elena Ciabatti, Carmen Fava, Antonio D'Avolio, Giulia Fontanelli, Giovanna Rege Cambrin, Alessandro Isidori, Federica Loscocco, Giovanni Caocci, Marianna Greco, Monica Bocchia, Lara Aprile, Antonella Gozzini, Barbara Scappini, Daniele Cattaneo, Anna Rita Scortechini, Giorgio La Nasa, Alberto Bosi, Pietro Leoni, Romano Danesi, Giuseppe Saglio, Giuseppe Visani, Agostino Cortelezzi, Mario Petrini, Alessandra Iurlo, Antonello Di Paolo
First-line nilotinib in chronic myeloid leukemia is more effective than imatinib to achieve early and deep molecular responses, despite poor tolerability or failure observed in one-third of patients. The toxicity and efficacy of tyrosine kinase inhibitors might depend on the activity of transmembrane transporters. However, the impact of transporters genes polymorphisms in nilotinib setting is still debated. We investigated the possible correlation between single nucleotide polymorphisms of hOCT1 (rs683369 [c...
October 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/29150293/a-unique-and-promising-combination-of-medications-for-the-treatment-of-alzheimer-s-disease
#11
James D Weinstein
At present there is no therapy for Alzheimer's Disease which completely stops the progressive dementia effecting late onset Alzheimer's Disease (AD) patients. It is felt that the main reason for this failure is that AD appears to be a disease caused by four major pathological processes. To date, efforts to develop treatments have addressed only one or another of these four etiologies. However, even a partially effective therapy against one cause allows the others, untreated, to continue their inexorable destruction of the neurons of the brain...
November 2017: Medical Hypotheses
https://www.readbyqxmd.com/read/29136709/-the-clinical-analysis-of-frontline-nilotinib-vs-imatinib-therapies-for-newly-diagnosed-chronic-myeloid-leukemia-in-chronic-phase
#12
H Yin, L F Chen, J K Cui, Y Y Xiong, Y You, P Zou, W M Li
Objective: To compare the clinical efficacy and safety of nilotinib and imatinib as frontline therapy in newly diagnosed patients with chronic myeloid leukemia in chronic phase(CML-CP). Methods: Until December 31st 2016, 18 patients using nilotinib and 83 using imatinib were recruited in our study. The efficacy and safety of two groups were evaluated. Results: A total of 101 patients with CML-CP included 18 receiving nilotinib and 83 imatinib. The optimal response rates at 3, 6, 12 and 18 months in nilotinib and imatinib group were 88...
November 1, 2017: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/29128554/immunomodulatory-effects-of-tyrosine-kinase-inhibitor-in-vitro-and-in-vivo-study
#13
Elena Marinelli Busilacchi, Andrea Costantini, Nadia Viola, Benedetta Costantini, Jacopo Olivieri, Luca Butini, Giorgia Mancini, Ilaria Scortechini, Martina Chiarucci, Monica Poiani, Antonella Poloni, Pietro Leoni, Attilio Olivieri
Pathogenesis of chronic graft-versus-host disease (cGVHD) is incompletely defined, involving donor-derived CD4 and CD8-positive T lymphocytes as well as B cells. Standard treatment is lacking for steroid-dependent/refractory cases; therefore, the potential usefulness of tyrosine kinase inhibitors (TKIs) has been suggested, based on their potent antifibrotic effect. However, TKIs seem to have pleiotropic activity. We sought to evaluate the in vitro and in vivo impact of different TKIs on lymphocyte phenotype and function...
November 8, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29124948/tasigna-nilotinib-in-chronic-myeloid-leukemia%C3%A2-treatment-free-remission-after-nearly-2%C3%A2-years-an-interview-with-adam-mead
#14
Adam Mead
Dr Mead earned his medical degree from the University of Oxford and trained in hematology at St Bartholomew's Hospital and University College London. In 2007, he earned his PhD at UCL, which focused on the analysis of FLT3 mutations in acute myeloid leukemia. He is now Associate Professor of Hematology and MRC Senior Clinical Fellow at the WIMM, University of Oxford. His research group focuses on myeloid diseases and normal blood stem-cell biology. Dr Mead is the lead clinician for myeloproliferative neoplasms (MPN) and chronic myeloid leukemia in the Thames Valley Strategic Clinical Network and is the chief investigator for several chronic myeloid leukemia and MPN clinical trials...
November 10, 2017: Future Oncology
https://www.readbyqxmd.com/read/29115640/off%C3%A2-target-effect-of-imatinib-and-nilotinib-on-human-vitamin-d3-metabolism
#15
Lysann Kroschwald, Meinolf Suttorp, Josephine Tabea Tauer, Nick Zimmermann, Claudia Günther, Andrea Bauer
Prolonged treatment with tyrosine kinase inhibitors (TKI) including imatinib (IMA) or nilotinib (NIL), induces severe disturbances of bone metabolism in patients with chronic myeloid leukaemia. As vitamin D3 (VD3) is involved in the complex cycle of bone remodelling, the present study investigated in vitro, the influence of IMA and NIL on VD3 metabolism i) in HaCaT cells and ii) in cultured outer root sheath keratinocytes (ORS‑KC) from hair follicles of IMA treated children. Cells were incubated in the presence of IMA or NIL...
November 3, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29095654/incidence-of-type-2-diabetes-mellitus-and-hyperlipidemia-in-patients-prescribed-dasatinib-or-nilotinib-as-first-or-second-line-therapy-for-chronic-myelogenous-leukemia-in-the-us
#16
Meg Franklin, Leah Burns, Samuel Perez, Deepak Yerragolam, Dinara Makenbaeva
OBJECTIVE: Evaluate the incidence of Type 2 Diabetes Mellitus (T2DM) and hyperlipidemia (HLD) in CML patients initiating therapy with dasatinib or nilotinib. METHODS: Retrospective study using MarketScan claims from 1/2006-12/2014. The first analysis evaluated occurrence of T2DM, defined as ≥2 claims with a T2DM ICD-9 code or 1 diagnosis claim and an anti-diabetic medication. The second analysis evaluated occurrence of HLD, defined as ≥2 claims with an HLD ICD-9 code, or 1 diagnosis claim and an anti-HLD medication...
November 2, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29076005/nilotinib-vs-imatinib-in-japanese-patients-with-newly-diagnosed-chronic-myeloid-leukemia-in-chronic-phase-long-term-follow-up-of-the-japanese-subgroup-of-the-randomized-enestnd-trial
#17
Hirohisa Nakamae, Tetsuya Fukuda, Chiaki Nakaseko, Yoshinobu Kanda, Ken Ohmine, Takaaki Ono, Itaru Matsumura, Akira Matsuda, Makoto Aoki, Kazuo Ito, Hirohiko Shibayama
In the ongoing, international, phase 3 study Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd), nilotinib 300 and nilotinib 400 mg, both twice daily, are compared with imatinib 400 mg once daily for the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase (CML-CP). Results for the overall population in ENESTnd (n = 846) showed that nilotinib resulted in higher response rates vs. imatinib and was well tolerated. Outcomes among Japanese patients in ENESTnd were specifically analyzed after 1 year of follow-up, and showed similar trends to the overall population; we present updated analysis of the Japanese subgroup based on 5 years of follow-up...
October 26, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29063181/correction-to-an-analysis-of-the-kinetics-of-molecular-response-during-the-first-trimester-of-treatment-with-nilotinib-in-newly-diagnosed-chronic-myeloid-leukemia-patients-in-chronic-phase
#18
Juan Luis Steegmann, Dolors Colomer, Maria-Teresa Gómez-Casares, Valentín García-Gutiérrez, Guillermo Ortí, Angel Ramírez-Payer, Eduardo Olavarria, Ferrán Vall-Llovera, Pilar Giraldo, Eulogio Conde, Rolando Vallansot, Jose Luis López-Lorenzo, Luis Palomera, Alberto Álvarez-Larrán, Venancio Conesa, Guiomar Bautista, Laura Casas, Frank Giles, Andreas Hochhaus, Luis Felipe Casado-Montero
Correction to: J Cancer Res Clin Oncol (2017) 143:2059-2066 DOI 10.1007/s00432-017-2445-z.
October 23, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29051802/radotinib-and-its-clinical-potential-in-chronic-phase-chronic-myeloid-leukemia-patients-an-update
#19
REVIEW
Ahmet Emre Eskazan, Dilek Keskin
Although imatinib has dramatically improved major outcomes in patients with chronic myeloid leukemia (CML), there are newer tyrosine kinase inhibitors (TKIs) approved worldwide for the treatment of resistant cases, and two second-generation TKIs (dasatinib, nilotinib) are approved in some nations for treating patients in the upfront setting. Radotinib (IY5511HCL, Supect®) is a novel and selective second-generation BCR-ABL1 TKI, which is currently approved in Korea for the treatment of patients with CML both in the upfront and salvage settings...
September 2017: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/29051021/anti-pdgfra-antibodies-predict-for-response-to-nilotinib-in-steroid-refractory-dependent-cgvhd
#20
George L Chen, Paul A Carpenter, Raewyn Broady, Tara K Gregory, Laura J Johnston, Barry E Storer, Jan H Beumer, Jingxin Qiu, Kiara Cerda, Ryan Le, Joanne M Otani, Hong Liu, Maureen A Ross, Sally Arai, Mary E D Flowers, Philip L McCarthy, David B Miklos
Imatinib has clinical activity in chronic graft-versus-host disease (cGvHD), a significant complication of allogeneic hematopoietic cell transplant. Nilotinib is a tyrosine kinase inhibitor that targets the same receptors as imatinib but with different affinities. We tested the hypothesis that nilotinib is safe and has clinical activity in cGvHD. 33 participants were enrolled in a phase 1/2 dose escalation and dose extension clinical trial of nilotinib for the treatment of steroid refractory or dependent cGvHD (ClinicalTrials...
October 16, 2017: Biology of Blood and Marrow Transplantation
keyword
keyword
20141
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"